SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Panacos Pharmaceuticals (PANC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (9)10/9/2006 1:05:45 PM
From: tuck  Read Replies (3) of 53
 
The safety, tolerability and pharmacokinetics of PA-457, a first-in-class HIV maturation inhibitor, in healthy volunteers

David E. Martin1, Charles H. Ballow2, Robert Blum2, Judy Doto1, Carl T. Wild1, and Graham P. Allaway1

1Panacos Pharmaceuticals, Inc., Gaithersburg, MD. 2Buffalo Clinical Research Center, Buffalo, New York.

12th Conference on Retroviruses and Opportunistic Infections, February 2005, Boston, MA

panacos.com

I didn't post the content because of the graphs. PK parameters look pretty linear in all cohorts.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News